FluidForm Bio

FluidForm Bio

Private
Waltham, MassachusettsHealthcare & Life Scienceshttps://www.fluidformbio.com/

Last Round

Crowdfunding

Apr 16, 2025

Total Funding Raised

$733,563

Momentum Score

25 /100

Company Overview

FluidForm Bio is a 3D bioprinting company developing a new class of life-extending tissue therapeutics to treat vascular disease using its patented FRESH™ 3D printing technology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical Devices, 3D Printing, Biotech Equipment

Business Model

B2B

Customer Profile

Services & Consulting, Hardware Sales, Government Contracts

AI Layer

Non-AI

Keywords

3D bioprintingtissue engineeringFRESH bioprintingregenerative medicineimplantable therapeuticsvascularized tissuebioprinting platformdrug discovery modelscell therapyType 1 diabetes treatmentbiofabricationtissue printingbioprinting consumablesbio-ink3D cell culturecollagen printing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

FluidForm Bio Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

FluidForm Bio Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
CrowdfundingApr 16, 2025
StrategicJan 11, 2022
GrantMay 1, 2021
GrantApr 1, 2021

Key People

Founding team and executive leadership

Adam Feinberg

CTO And Co-founder

Founding Team

Erik Waters

Chief Financial Officer

Executive Team

FluidForm Bio Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 20, 2026

    Monthly visitors grew 46% MoM, reaching 1.7K.

  • May 2, 2025

    Monthly visitors doubled, reaching 2,000.

FluidForm Bio Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

FluidForm Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about FluidForm Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersWaltham, Massachusetts
Employee Range14
Year Founded2018
Last FundingApr 16, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.